Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. The company is headquartered in Austin, Texas and currently employs 66 full-time employees. The company went IPO on 2000-09-29. The firm's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus is a reflex process of two tests, Ova1 and Overa, to assess the risk of ovarian malignancy in women with an adnexal mass planned for surgery. Its product pipelines are OVAinform and ENDOinform. OVAinform is a test that combines serum proteins, clinical data (metadata), and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass. ENDOinform is a test program that combines serum proteins, clinical data (metadata), and miRNA for the identification of endometriosis.
How did AWHL's recent EPS compare to expectations?
The most recent EPS for Aspira Women's Health Inc is $, expectations of $-0.12.
How did Aspira Women's Health Inc AWHL's revenue perform in the last quarter?
Aspira Women's Health Inc revenue for the last quarter is $
What is the revenue estimate for Aspira Women's Health Inc?
According to of Wall street analyst, the revenue estimate of Aspira Women's Health Inc range from $ to $
What's the earning quality score for Aspira Women's Health Inc?
Aspira Women's Health Inc has a earning quality score of /. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Aspira Women's Health Inc report earnings?
Aspira Women's Health Inc next earnings report is expected in 2026-06-24
What are Aspira Women's Health Inc's expected earnings?
Aspira Women's Health Inc expected earnings is $5.25M, according to wall-street analysts.
Did Aspira Women's Health Inc beat earnings expectations?
Aspira Women's Health Inc recent earnings of $ expectations.